Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMQYF6)

Drug Name

TRO-19622 Drug Info

Synonyms

Olesoxime; UNII-I2QN18P645; TRO 19622; NSC 21311; 22033-87-0; Cholest-4-en-3-one oxime; I2QN18P645; TRO-19622; Olesoxime, Z-; cholest-4-en-3-one, oxime; Olesoxime [USAN:INN]; SCHEMBL1010552; C27H45NO; QNTASHOAVRSLMD-FCARAQADSA-; MolPort-023-276-596; 3948AH; AKOS005145744; ZINC100657483; API0009039; 66514-00-9; 033T870; UNII-A6778U5IFY component QNTASHOAVRSLMD-FCARAQADSA-N

Indication

Disease Entry	ICD 11	Status	REF
Peripheral neuropathy	8C0Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 9930827
CAS Number: CAS 66538-08-7
TTD Drug ID: DMMQYF6

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glutamate receptor AMPA (GRIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Halothane	DM80OZ5	Anaesthesia	9A78.6	Approved	[3]
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[4]
Zopiclone	DMPI6Z0	Insomnia	7A00-7A0Z	Approved	[5]
Sevoflurane	DMC9O43	Anaesthesia	9A78.6	Approved	[6]
Enflurane	DM0YJSB	Anaesthesia	9A78.6	Approved	[7]
Isoflurane	DMY6T31	Anaesthesia	9A78.6	Approved	[8]
Bromazepam	DMY9TCW	Anxiety disorder	6B00-6B0Z	Approved	[9]
Artemisinin SP	DMFETDK	Malaria	1F40-1F45	Approved	[10]
Dihydroergotoxine	DM5D6WZ	Alzheimer disease	8A20	Approved	[11]
Barbiturate	DMJIA6T	Anaesthesia	9A78.6	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8542).
2	Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
3	Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
4	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
5	Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
6	Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
7	Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
8	Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
9	Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
10	GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
11	Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
12	Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.